Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2007

Neuropsychiatrie, Decouverte & Innovation Collaborates with Genizon on Schizophrenia Research

  • Genizon BioSciences and Neuropsychiatrie, Decouverte & Innovation (NDEI) will work together to enhance discoveries made by Genizon earlier this year in a genome wide association study of schizophrenia.

    Genizon's previous work identified multiple genes associated with the disease using DNA samples from patients in the Quebec Founder Population. The population which, because of its high level of genetic homogeneity, is considered among the best for disease gene discovery, according to the companies.

    Under the terms of the agreement, NDEI will be supplying a second set of samples collected from the Quebec Founder Population. Genotyping of these samples and statistical analyses of the data will be conducted at Genizon's St. Laurent, Quebec, research center.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »